抗CD3-EGFR双特异性抗体标记DC-CIK免疫细胞的制备及其临床安全性研究  

作　　者：吴中杰 胡奕 张雁飞 苗瀛 吴滌樊 徐荻 

机构地区：[1]浙江省嘉兴市第一医院,314000 [2]上海宇研生物技术有限公司,200062

出　　处：《浙江临床医学》2018年第4期635-637,共3页Zhejiang Clinical Medical Journal

基　　金：浙江省嘉兴市科技计划项目（2016AY23040）

摘　　要：目的赋予DC—CIK对于EGFRHEI性的肺癌细胞特异性的杀伤功能，为晚期肺癌患者提供-种安全高效的免疫治疗方法。方法用化学偶联法将抗CD3单克隆抗体和抗EGFR单克隆抗体偶联，并标记于DC-CIK细胞表面，体外评价安全有效；将晚期肺癌患者外周血分离得到PBMC，诱导扩增为DC-CIK细胞后，与抗CD3-EGFR双特异性抗体孵育，对15例晚期肺癌患者进行1-6个疗程的静脉回输治疗。结果双标记能显著提高DC-CIK细胞对EGFR阳性肺癌A549肿瘤细胞的杀伤活性。疗程结束后所有患者均无明显不良反应，生活质量评分得到明显改善，在观察期内所有患者未出现转移和复发。结论用抗CD3-EGFR双特异性抗体标记的DC-CIK免疫细胞具有良好的安全性，并对肿瘤有一定的抑制转移和复发的作用。Objective To investigate the specific killing function of DC-CIK on EGFR positive lung cancer cells and provide a safe and effective immunotherapy for patients with advanced lung cancer. Methods The anti CD3 monoclonal antibody and anti EGFR monoclonal antibody were coupled with chemical coupling method and labeled on the surface of DC-CIK cells. The evaluation was safe and effective in vitro; the peripheral blood of patients with lung cancer induced by isolated PBMC, amplified to DC-CIK cells, and anti CD3-EGFR bispecific antibody incubation, 1~6 treatment in 15 advanced lung cancer patients with venous transfusion. Result The results of double labeling significantly improved the A549 of tumor cells on DC-CIK cells in EGFR positive lung cancer killing activity. After the course of treatment, all the patients had no obvious adverse reactions, and the quality of life score improved obviously. All the patients had no metastasis or recurrence during the observation period. Conclusion The anti CD3-EGFR bispecific antibody labeled DC-CIK immune cells has good safety and has a certain effect on tumor metastasis and recurrence.

关 键 词：双特异性抗体 DC-CIK EGFR 晚期肺癌 

分 类 号：R392-33[医药卫生—免疫学]